IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of the Phase I part of this clinical research study is to find the highest tolerable
dose of the drug Yervoy (ipilimumab) that can be given with the drugs Intron-A (interferon
alfa-2b) and Proleukin (aldesleukin, IL-2) to patients with metastatic melanoma. The safety
of this combination will also be studied in Phase I. The goal of Phase II is to learn if this
combination can help to control metastatic melanoma.
Ipilimumab, interferon alfa-2b, and aldesleukin are designed to block the activity of cells
that decrease the immune system's ability to fight cancer.